AMOD vs SLXN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SLXN Captures Institutional Edge (2โ1 Pillars ยท 2โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Silexion Therapeutics Corp Ordinary Shares (SLXN) driven by superior Growth & Margin, Momentum & Technical while AMOD counters with relative strength in Options & Structure. Fundamentally, AMOD trades at N/M Forward P/E with -127536.2% operating margin (+0.0% YoY revenue) versus SLXN at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, AMOD sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against SLXN sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | AMOD | SLXN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $51.2M | $1.3M | Larger Scale | AMOD |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +0.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | -127536.2% | 0.0% | Higher Margin | SLXN |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | 0.0% | -897.5% | Higher ROE | AMOD |
| 52-Week Range Position Momentum | 11% ($0โ$7) | 31% ($0โ$5) | Stronger Trend | SLXN |
| Beta / 30D Volatility Risk Regime | 51.09ฮฒ ยท 120% Vol | 28.94ฮฒ ยท 9931% Vol | Lower Realized Risk | AMOD |
| Unified Institutional Score Composite Signal | 45.4 / 100 (HOLD) | 24.1 / 100 (STRONG SELL) | Higher Composite | AMOD |